Literature DB >> 23188388

Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions.

Michihiro Nakayama1, Atsutaka Okizaki, Shunta Ishitoya, Miki Sakaguchi, Junichi Sato, Tamio Aburano.   

Abstract

PURPOSE: The purpose of the present study is to evaluate the clinical value of dual-time-point F-18 FDG PET/CT imaging to differentiate malignant lymphoma (ML) from benign lymph node (BLN).
MATERIALS AND METHODS: The subjects were 310 lymph nodes in 84 patients (195 ML lesions in 30 patients and 115 BLN in 54 patients associated with various etiologies.). F-18 FDG PET/CT scan was performed at 50 min (early scan) and at 100 min (delayed scan) after the injection. First, the maximum standardized uptake value (SUVmax) of each lesion at early and delayed scans was calculated. Second, we estimated the difference between early and delayed SUVmax (D-SUVmax) and the retention index (RI-SUVmax) to evaluate the change of tracers in the lesions. Furthermore, proper cut-off values of them were evaluated using receiver operating characteristic analysis. The efficacy of each parameter was analyzed with ANOVA.
RESULTS: Delayed SUVmax and D-SUVmax in ML were significantly higher than those in BLN. Proper cut-off value in delayed SUVmax was 4.0 and in D-SUVmax was 1.0. When the proper cut-off value in D-SUVmax was applied, the D-SUVmax yielded the role of diagnosis with sensitivity of 82.6%, specificity of 65.2%, positive predictive value of 80.1% and negative predictive value of 68.8%, respectively.
CONCLUSIONS: The delayed SUVmax and D-SUVmax were useful indices to differentiate ML from BLN, regardless of histologic subtype. Dual-time-point F-18 FDG PET/CT imaging may help to consider whether there is any need to proceed to more invasive tests, such as biopsy, in individual patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23188388      PMCID: PMC3575551          DOI: 10.1007/s12149-012-0669-1

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  36 in total

1.  Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma.

Authors:  Takayoshi Shinya; Soichiro Fujii; Shoji Asakura; Toshitaka Taniguchi; Kotaro Yoshio; Aierken Alafate; Shuhei Sato; Tadashi Yoshino; Susumu Kanazawa
Journal:  Ann Nucl Med       Date:  2012-06-13       Impact factor: 2.668

2.  A PET study of 18FDG uptake in soft tissue masses.

Authors:  M A Lodge; J D Lucas; P K Marsden; B F Cronin; M J O'Doherty; M A Smith
Journal:  Eur J Nucl Med       Date:  1999-01

3.  Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck.

Authors:  R Hustinx; R J Smith; F Benard; D I Rosenthal; M Machtay; L A Farber; A Alavi
Journal:  Eur J Nucl Med       Date:  1999-10

Review 4.  Sarcoidosis and lymphoma: case series and literature review.

Authors:  H Maayan; Y Ashkenazi; A Nagler; G Izbicki
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2011-10       Impact factor: 0.670

5.  Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.

Authors:  Y Nakamoto; T Higashi; H Sakahara; N Tamaki; M Kogire; R Doi; R Hosotani; M Imamura; J Konishi
Journal:  Cancer       Date:  2000-12-15       Impact factor: 6.860

Review 6.  Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation.

Authors:  G J Cook; I Fogelman; M N Maisey
Journal:  Semin Nucl Med       Date:  1996-10       Impact factor: 4.446

7.  Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions.

Authors:  N Gupta; H Gill; G Graeber; H Bishop; J Hurst; T Stephens
Journal:  Chest       Date:  1998-10       Impact factor: 9.410

8.  Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.

Authors:  Kazuyoshi Suga; Yasuhiko Kawakami; Atsuto Hiyama; Kazurou Sugi; Kazutomo Okabe; Tsuneo Matsumoto; Kazuhiro Ueda; Nobuyuki Tanaka; Naofumi Matsunaga
Journal:  Ann Nucl Med       Date:  2009-05-15       Impact factor: 2.668

9.  The usefulness of a repeat study for differentiating between bowel activity and local tumor recurrence on FDG PET scans.

Authors:  Hyolim Chun; Chun K Kim; Borys R Krynckyi; Josef Machac
Journal:  Clin Nucl Med       Date:  2003-08       Impact factor: 7.794

10.  Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer.

Authors:  Daisuke Uesaka; Yoshiki Demura; Takeshi Ishizaki; Shingo Ameshima; Isamu Miyamori; Masato Sasaki; Yasuhisa Fujibayashi; Hidehiko Okazawa
Journal:  J Nucl Med       Date:  2008-09-15       Impact factor: 10.057

View more
  16 in total

1.  Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results.

Authors:  Sofie Bæk Christlieb; Casper Nørgaard Strandholdt; Birgitte Brinkmann Olsen; Karen Juul Mylam; Thomas Stauffer Larsen; Anne Lerberg Nielsen; Max Rohde; Oke Gerke; Karen Ege Olsen; Michael Boe Møller; Bjarne Winther Kristensen; Niels Abildgaard; Abass Alavi; Poul Flemming Høilund-Carlsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-22       Impact factor: 9.236

Review 2.  Advances in Imaging and Automated Quantification of Malignant Pulmonary Diseases: A State-of-the-Art Review.

Authors:  Bruno Hochhegger; Matheus Zanon; Stephan Altmayer; Gabriel S Pacini; Fernanda Balbinot; Martina Z Francisco; Ruhana Dalla Costa; Guilherme Watte; Marcel Koenigkam Santos; Marcelo C Barros; Diana Penha; Klaus Irion; Edson Marchiori
Journal:  Lung       Date:  2018-10-09       Impact factor: 2.584

3.  Differentiation of HIV-associated lymphoma from HIV-reactive adenopathy using quantitative FDG-PET and symmetry.

Authors:  Mike Sathekge
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04       Impact factor: 9.236

4.  The clinical value of texture analysis of dual-time-point 18F-FDG-PET/CT imaging to differentiate between 18F-FDG-avid benign and malignant pulmonary lesions.

Authors:  Masatoyo Nakajo; Megumi Jinguji; Masaya Aoki; Atsushi Tani; Masami Sato; Takashi Yoshiura
Journal:  Eur Radiol       Date:  2019-11-14       Impact factor: 5.315

5.  Dual time point fluorodeoxyglucose positron emission tomography/computed tomography in differentiation between malignant and benign lesions in cancer patients. Does it always work?

Authors:  Hussein Rabie Saleh Farghaly; Mohamed Hosny Mohamed Sayed; Hatem Ahmed Nasr; Ahmed Marzok Abdelaziz Maklad
Journal:  Indian J Nucl Med       Date:  2015 Oct-Dec

6.  Feasibility of a multimodal (18)F-FDG-directed lymph node surgical excisional biopsy approach for appropriate diagnostic tissue sampling in patients with suspected lymphoma.

Authors:  Stephen P Povoski; Nathan C Hall; Douglas A Murrey; Chadwick L Wright; Edward W Martin
Journal:  BMC Cancer       Date:  2015-05-08       Impact factor: 4.430

7.  Evaluation of a Fast Protocol for Staging Lymphoma Patients with Integrated PET/MRI.

Authors:  Johannes Grueneisen; Lino Morris Sawicki; Benedikt Michael Schaarschmidt; Saravanabavaan Suntharalingam; Sara von der Ropp; Axel Wetter; Verena Ruhlmann; Harald H Quick; Michael Forsting; Lale Umutlu
Journal:  PLoS One       Date:  2016-06-21       Impact factor: 3.240

8.  18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and background tissues.

Authors:  Stephen P Povoski; Douglas A Murrey; Sabrina M Smith; Edward W Martin; Nathan C Hall
Journal:  BMC Cancer       Date:  2014-06-19       Impact factor: 4.430

9.  Optimal scan time for evaluation of parathyroid adenoma with [(18)F]-fluorocholine PET/CT.

Authors:  Sebastijan Rep; Luka Lezaic; Tomaz Kocjan; Marija Pfeifer; Mojca Jensterle Sever; Urban Simoncic; Petra Tomse; Marko Hocevar
Journal:  Radiol Oncol       Date:  2015-11-27       Impact factor: 2.991

10.  Relationship Between Dual Time Point FDG PET/CT and Clinical Prognostic Indexes in Patients with High Grade Lymphoma: a Pilot Study.

Authors:  Do Hyoung Lim; Jai Hyuen Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.